Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor Constance KingHenry DiazMark Marshall PRECLINICAL STUDIES 10 October 2013 Pages: 213 - 226
Synthesis and in vitro characterization of ionone-based compounds as dual inhibitors of the androgen receptor and NF-κB Weiguo LiuJinming ZhouJian Hui Wu PRECLINICAL STUDIES 23 October 2013 Pages: 227 - 234
HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer Guru SonpavdeMingjun WangTeresa G. Hayes PHASE I STUDIES 23 April 2013 Pages: 235 - 242
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575) Suzanne RichterPhilippe L. BedardElaine McWhirter PHASE I STUDIES Open access 05 May 2013 Pages: 243 - 249
A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma R. C. TurkingtonC. PurcellM. M. Eatock PHASE I STUDIES 11 May 2013 Pages: 250 - 260
Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer Narikazu BokuKei MuroYoshinori Miyata PHASE I STUDIES Open access 12 May 2013 Pages: 261 - 270
Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer Changhoon YooMin-Hee RyuYoon-Koo Kang PHASE I STUDIES 28 May 2013 Pages: 271 - 278
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer Prasanth GanesanSarina Piha-PaulApostolia M. Tsimberidou PHASE I STUDIES 12 June 2013 Pages: 279 - 286
Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study J. Martín-LiberalA. López-PousaX. García del Muro PHASE I STUDIES 26 June 2013 Pages: 287 - 294
A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer William R. SchelmanTabraiz A. MohammedGlenn Liu PHASE I STUDIES 17 July 2013 Pages: 295 - 302
Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study Patricia M. LoRussoSmitha KrishnamurthiScot Remick PHASE I STUDIES 01 August 2013 Pages: 303 - 311
Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples Vladimir LazarNathalie LassauJean-Pierre Armand PHASE I STUDIES 27 August 2013 Pages: 312 - 322
A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors Dustin A. DemingJacob NinanWilliam R. Schelman PHASE I STUDIES 10 October 2013 Pages: 323 - 329
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer John H. StricklerShannon McCallHerbert I. Hurwitz PHASE I STUDIES 01 November 2013 Pages: 330 - 339
Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors Woondong JeongSook Ryun ParkShivaani Kummar PHASE I STUDIES 16 November 2013 Pages: 340 - 346
Safety, tolerability, and pharmacokinetics of the novel αv-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses Wolfgang UhlMichael ZühlsdorfAndreas Kovar PHASE I STUDIES Open access 19 November 2013 Pages: 347 - 354
A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer Yoon-Koo KangKei MuroNarikazu Boku PHASE II STUDIES 15 December 2013 Pages: 355 - 361
Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer Neelesh SharmaNathan PennellAfshin Dowlati PHASE II STUDIES 15 January 2014 Pages: 362 - 368
A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis Jae-Cheol JoYong Sang HongTae Won Kim PHASE II STUDIES 16 January 2014 Pages: 369 - 376
Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC) Carlos Alvarez-FernandezQuionia Perez-ArnillasEmilio Esteban-Gonzalez SHORT REPORT 04 August 2013 Pages: 377 - 381
Low skeletal muscle is associated with toxicity in patients included in phase I trials Sophie CousinA. HollebecqueS. Antoun SHORT REPORT 17 December 2013 Pages: 382 - 387
Erratum to: Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics Yu SunakawaJunji FuruseYasutsuna Sasaki Erratum 03 September 2013 Pages: 388 - 388